Concourse Financial Group Securities, Inc. Biocryst Pharmaceuticals Inc Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	BUY	$6.41 - $8.69 $0 - $0	0 New	0 $0
Q2 2024 Jul 23, 2024	SELL	$4.13 - $6.79 $5,369 - $8,827	-1,300 Closed	0 $0
Q3 2023 Oct 25, 2023	SELL	$6.71 - $7.92 $6 - $7	-1 Reduced 0.08%	1,300 $9,000
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $7 - $11	1 Added 0.08%	1,301 $10,000
Q1 2022 May 09, 2022	BUY	$11.56 - $19.76 $5,780 - $9,880	500 Added 62.5%	1,300 $21,000
Q3 2020 Nov 13, 2020	BUY	$3.43 - $5.53 $2,744 - $4,424	800 New	800 $3,000
Q2 2020 Aug 13, 2020	BUY	$1.9 - $5.61 $0 - $0	0 New	0 $0
Q1 2020 May 13, 2020	BUY	$1.6 - $4.11 $0 - $0	0 New	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $0 - $0	0 New	0 $0
Q3 2019 Nov 13, 2019	BUY	$2.5 - $3.73 $0 - $0	0 New	0 $0
Q2 2019 Aug 13, 2019	BUY	$2.91 - $9.15 $0 - $0	0 New	0 $0
Q1 2019 May 15, 2019	BUY	$7.38 - $9.72 $0 - $0	0 New	0 $0
Q4 2018 Feb 14, 2019	BUY	$6.51 - $9.6 $0 - $0	0 New	0 $0
Q3 2018 Nov 13, 2018	BUY	$5.52 - $7.99 $0 - $0	0 New	0 $0

Others Institutions Holding BCRX

# of Institutions

280

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

Vanguard Group Inc Valley Forge, PA

20.3M
Shares

$152 Million
0.0% of portfolio
Black Rock Inc. New York, NY

20M
Shares

$149 Million
0.0% of portfolio
Avoro Capital Advisors LLC New York, NY

11.9M
Shares

$88.9 Million
1.36% of portfolio
Kynam Capital Management, LP Princeton, NJ

9.09M
Shares

$68 Million
5.66% of portfolio
State Street Corp Boston, MA

8.85M
Shares

$66.3 Million
0.0% of portfolio

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account